课题基金 / 基金详情

Targeted Gold Nanoparticle-Bioconjugates for Imaging Breast Cancer

Targeted Gold Nanoparticle-Bioconjugates for Imaging Breast Cancer
用于乳腺癌成像的靶向金纳米颗粒生物共轭物
批准号:
7618631
负责人:
Raghuraman Kannan
金额:
$14.95万
依托单位国家:
美国
项目类别:
财政年份:
2007
资助国家:
美国
项目状态:
已结题
起止时间:
2007-06-20 至 2012-05-31

项目摘要

项目成果

Raghuraman Kannan的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): This application describes the design of new gold nanoparticle based bioconjugates derived from synthetic bombesin (BBN) analogues to produce a new generation of site-directed computed tomography (CT) imaging agents for specific in vivo targeting of breast cancer cells. With the overarching goal of visualizing smaller lesion (and therefore earlier cancer detection) with better specificity, this work has the potential to increase the survival rate from breast cancer. Specifically, this application will explore whether targeted gold nanoparticles are capable of producing contrast enhancement (increased x-ray attenuation) so that CT can be used in precise and accurate functional/molecular imaging of breast cancer. Our specific aims for the proposed project are to: (i) Optimize synthetic protocols for targeted gold nanoparticles (AuNPs) conjugated to tumor specific peptide; (ii) Determine the concentrations of gold nanoparticles necessary to induce image contrast in CT imaging using anthropomorphic phantom models of the human breast, including malignant lesions; and (iii) Investigate the utility of Bombesin conjugated AuNPs as image enhancers in computer tomographic (CT) imaging of breast tumors in SCID mice implanted with human breast cancer xenografts. Phantom studies will be performed to evaluate the concentration of AuNP required to produce sufficient contrast to effectively detect breast cancer for a specifically designed Breast CT scanner. This assessment will be done with respect to radiation dose and the size of the lesion; it is anticipated that improved contrast will lead to earlier detection of minimal breast cancer (in situ and minimally invasive). Approaches and methods to conjugate different sizes and shapes of gold nanoparticles (AuNPs) with synthetic BBN analogues that maintain or enhance high breast cancer cell binding with good in vitro and in vivo stability, will be developed. The most promising targeted AuNP-BBN candidates will be evaluated in SCID mice implanted with breast tumor xenografts, to assess their ability to target breast tumors. The goal of these studies is to provide targeted AuNP-BBN analogues that could be developed, via human clinical trials, into effective molecular imaging agents for early diagnostic application in breast tumor patients. The specific objective of our application encompassing the development of new molecular imaging probes, for the early detection of breast cancer, using nanotechnology principles is directly relevant to the overall outcomes sought within the current RFA "PAR-06-475- Nanoscience and nanotechnology in Biology and Medicine (R21)". The proposed work will develop an enhancement of current Computer Tomography (CT) imaging of the breast. The research will utilize nanosized gold particles that are approximately 1000 times smaller than a human cell to generate X-ray contrast that would be detected by a CT-imaging instrument external to the body. If molecules specific to breast cancer are attached to the gold nanoparticles so that they locate in the cells of breast cancer, the contrast generated would allow the cancer to be more readily detected. This has the potential to improve the early detection and diagnosis of breast cancer.
期刊论文(11)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1166/jbn.2014.1725
发表时间: 2014-03
期刊: Journal of biomedical nanotechnology
影响因子: 2.9
作者: [N. Chanda;Anandhi Upendran;E. Boote;Ajit P. Zambre;S. Axiak;K. Selting;K. Katti;W. Leevy;Z. Afrasiabi;Jatin Vimal;Jason Singh;J. Lattimer;R. Kannan]
通讯作者: N. Chanda;Anandhi Upendran;E. Boote;Ajit P. Zambre;S. Axiak;K. Selting;K. Katti;W. Leevy;Z. Afrasiabi;Jatin Vimal;Jason Singh;J. Lattimer;R. Kannan
DOI: 10.1016/j.ica.2011.01.065
发表时间: 2011-06-15
期刊: Inorganica chimica acta
影响因子: 2.8
作者: [Sleightholm L, Zambre A, Chanda N, Afrasiabi Z, Katti K, Kannan R]
通讯作者: Kannan R
DOI: 10.1039/b822015h
发表时间: 2009-06-01
期刊: Journal of materials chemistry
影响因子: --
作者: [Nune SK, Chanda N, Shukla R, Katti K, Kulkarni RR, Thilakavathi S, Mekapothula S, Kannan R, Katti KV]
通讯作者: Katti KV
DOI: 10.1166/jbn.2010.1105
发表时间: 2010-04
期刊: Journal of biomedical nanotechnology
影响因子: 2.9
作者: [J. Viator;Sagar K. Gupta;Benjamin S. Goldschmidt;K. Bhattacharyyal;R. Kannan;R. Shukla;P. Dale;E. Boote;K. Katti]
通讯作者: J. Viator;Sagar K. Gupta;Benjamin S. Goldschmidt;K. Bhattacharyyal;R. Kannan;R. Shukla;P. Dale;E. Boote;K. Katti
7
    Towards Translation of MU-CN29: New Therapeutic Nanoparticle for Drug-Resistant NSCLC
    • 批准号:
      10529911
    • 项目类别:
    • 资助金额:
      $62.21万
    • 财政年份:
      2022
    • 负责人:
      Raghuraman Kannan
    • 依托单位:
    Towards Translation of MU-CN29: New Therapeutic Nanoparticle for Drug-Resistant NSCLC
    • 批准号:
      10649533
    • 项目类别:
    • 资助金额:
      $57.84万
    • 财政年份:
      2022
    • 负责人:
      Raghuraman Kannan
    • 依托单位:
    Engineering Dual-Targeted Nanoplatforms to Effectively Treat NSCLC.
    • 批准号:
      10705589
    • 项目类别:
    • 资助金额:
      $66.1万
    • 财政年份:
      2022
    • 负责人:
      Raghuraman Kannan
    • 依托单位:
    Targeted Gold Nanoparticle-Bioconjugates for Imaging Breast Cancer
    • 批准号:
      7278911
    • 项目类别:
    • 资助金额:
      $14.95万
    • 财政年份:
      2007
    • 负责人:
      Raghuraman Kannan
    • 依托单位:
    海外基金